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The virulence and pathogenicity of various types of Toxoplasma gondii differ
considerably in mice. Recent studies have claimed that similar phenomenon was
observed in humans, but no relevant studies have been performed to validate this
ﬁnding. In addition, reports showing association between a given T. gondii type and
outcomes of human infection yielded conﬂicting results. To provide a more precise
estimation of the association and a more reliable conclusion on this subject, we
performed this meta-analysis. Relevant literatures were identiﬁed in multiple data-
bases and selected based on strict screening. T. gondii-type proportions among
different severities of infection were calculated and compared using Fisher’s exact
test. Pooled odds ratios (OR) were calculated. Our results showed that the difference
among T. gondii-type proportions was signiﬁcant (p < 0.0001). In addition, signiﬁcant
associations were detected between Type I strains infection and congenital toxoplas-
mosis (OR: 1.91, p= 0.0009), Type III strains infection and pulmonary toxoplasmosis
(OR: 5.15, p = 0.04). In our subgroup analysis, Type I strains were signiﬁcantly
associated with cerebral toxoplasmosis in offspring (OR: 1.81, p = 0.02). This result
indicated that different types of T. gondii exhibited different virulence and caused
different outcomes in humans.
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Introduction
The obligate intracellular protozoan Toxoplasma gondii is capable of
infecting a broad spectrum of warm-blooded vertebrates, including humans [1].
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T. gondii infection is often acquired through ingestion of water or food that is
contaminated by infective oocysts, consumption of meat products containing viable
cysts, or vertical transmission of tachyzoites [2]. In humans, the clinical presenta-
tions of T. gondii infection vary from asymptomatic infection, or non-speciﬁc mild
symptoms, to severe toxoplasmosis [3, 4].
Howe and Sibley [5] originally found a highly clonal population structure of
the parasite, which fell into three predominant lineages (Types I, II, and III) by a
polymerase chain reaction-restriction fragment length polymorphism (PCR-
RFLP) analysis, employing 106 T. gondii isolates from Europe and North
America. Recently, a PCR-RFLP study employing about 1,500 samples world-
wide, revealed 189 different genotypes [6].
The clonal lineages have a number of different phenotypes, such as growth,
migration, and transmigration [7]; however, the best characterized of these is their
virulence in laboratory mice [8, 9]. Type I strains exhibit the acute lethal virulence
in laboratory mice [lethal dose (LD100) ≈ 1], whereas Type II and Type III strains
are much less virulent [median lethal dose (LD50) ≥ 105] [10, 11].
Several studies suggested that the type of T. gondii might be responsible for
the variability, or at least part of the variability, on the outcomes of human
infection, as it has been observed in laboratory mice [4, 12, 13]. In addition, the
growth rate of Type I strains in human foreskin ﬁbroblasts (HFFs) was about one
third higher than those of Type II and Type III strains, this fact might reﬂect that
the virulence difference in mice could extend to humans [4]. Accordingly, to
provide a more precise estimation of the association between T. gondii types and
outcomes of human infection, we performed this meta-analysis based on cross-
regional case–control studies, comprising a total of 1,891 individuals. However,
the case–control studies on the strain types not belonging to Types I, II, and III are
too limited to generate a meta-analysis, thus we mainly focused on the three clonal
lineages and the naturally recombinant strains, which might provide a reference of
the virulence in humans for the other types.
Materials and Methods
Search strategy
This meta-analysis was performed in accordance with the Cochrane Hand-
book for Systematic Reviews of Interventions [14] and the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [15]
(Supplementary Table I). From multiple databases, including PubMed, Cochrane
Library, Web of Science, and China National Knowledge Infrastructure (CNKI)
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database, with the following Medical Subject Heading (MeSH) search terms used
individually or in combination with the literature search: “Toxoplasma gondii,”
“type,” “case–control studies,” “cohort studies,” “human,” “asymptomatic,” “mild
symptoms,” and “toxoplasmosis,” a total of 1,560 potentially relevant citations
were identiﬁed. The reference lists of all retrieved articles were also scrutinized for
additional relevant studies.
Inclusion and exclusion criteria
After the exclusion of duplicate articles, the titles and abstracts of the
remaining articles were screened by two independent reviewers (JX and XY-C)
to identify eligible studies, this screening was followed by an assessment of the full
texts based on several criteria for inclusion and exclusion. The inclusion criteria
were as follows: (1) the published full text was available; (2) it was an observational
study (a case–control study or a cohort study); (3) sufﬁcient data were reported to
calculate the odds ratio (OR) or the risk ratio with their 95% conﬁdence intervals
(CIs); and (4) typing of T. gondii isolates was based on one of the following genetic
or serological methods: (a) PCR-RFLP analysis; (b) microsatellite analysis;
(c) multilocus sequence analysis; (d) random ampliﬁed polymorphic DNA-PCR;
(e) high-resolution melting; (f) ELISA format; (g) peptide-microarray test; or
(h) genotype or serotype of T. gondii that could be conﬁrmed by medical records.
Studies were excluded if they were (1) lacking any raw data or control subjects;
(2) included fewer than 10 participants; (3) comments, congresses, abstracts,
reviews, or editorials; or (4) reported mix infection (combination of more than
one type in one sample).
Data extraction
The following information were extracted in duplicate (JX and X-YC) from
all of the included studies: name of the ﬁrst author, publication year, country or
geographical region, speciﬁc descriptions of the infection, genetic markers for
genotyping, serological markers for serotyping, reference strain, genotype or
serotype, sample size, and the number of the exposure of interest for case–control
studies.
Quality assessment
To assess the methodological quality and risk of bias associated with the
included studies, we used the Newcastle–Ottawa Scale (NOS) (Supplementary
Table II). The studies that scored more stars were regarded to be of higher quality.
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Studies with four stars for selection, two stars for comparability, and three stars for
exposure were considered to have a low risk of bias. Studies having two or three
stars for selection, one for comparability, and two for exposure were regarded to
have a medium risk of bias. Studies provided with one star for selection or
exposure, or no star for any of the three parts, were deemed to have a high risk of
bias. Quality assessment and stars allocation were performed by two independent
reviewers (JX and X-YC).
Statistical analysis
Fisher’s exact test (Monte Carlo method) was conducted to examine the
discrepancy among the T. gondii-type proportions of different severities of human
infection, and multiple comparisons were performed using the Z-test (where
p values were adjusted by the Bonferroni method) [16]. Statistical heterogeneity
among studies was calculated using the χ2 test, p values, and I2 statistics [17]. A
random-effects analysis model was used to estimate the overall OR when
heterogeneity was signiﬁcant (Q: p ≤ 0.1 and I2 ≥ 50% or Q: p ≤ 0.1 and
I2 ≥ 25%); If the reverse was true, a ﬁxed-effects analysis model was used
(Q: p > 0.1 and I2 ≤ 50% or Q: p ≤ 0.1 and I2 < 25%). For the association between
T. gondii types and outcomes of human infection, the odds of a given T. gondii
type were compared in the case group (infected population with a given manifes-
tation) versus the control group (infected population without this manifestation).
The results were obtained after pooling estimates of each individual study, and
reported as the overall OR with a 95% CI by using Mantel–Haenszel statistical
method, and forest plot was also generated. Sensitivity analysis was conducted to
examine if the results were robust [18]. Funnel plot was created and its symmetry
was checked to evaluate publication bias [19]. Subgroup analysis of the relation-
ship between T. gondii types and congenital toxoplasmosis was performed.
Fisher’s exact test and Z-test were undertaken using IBM SPSS Statistics 20.0
[20]; risk estimates, test of heterogeneity, sensitivity calculation, and publication
bias analysis were performed using Review Manager software, version 5.3 [21].
Results
Deﬁnitions
The term “infection with mild symptoms” used in this study was based on
the ﬂu-like and self-limited symptoms of Toxoplasma-infected patients, including
fever, swollen lymph nodes, and muscle weakness. It should be noted that if the
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infected patient had “mild symptoms” at the early stage of infection, and
developed a severe toxoplasmosis later, then this case was classiﬁed as “toxo-
plasmosis.” It was also critical to point out that the strain types not belonging to the
three clonal lineages (Types I, II, and III) or recombinant (Types I/II, I/III, and
II/III), and the strain types described as “atypical,” “exotic,” or “unique” directly in
the included studies, were deﬁned as “the other types” in this study.
Study characteristics
Of the 1,560 potentially relevant citations identiﬁed, 39 case–control studies
published in 15 articles [22–36], comprising a total of 1,891 individuals, met the
study criteria and were included in our meta-analysis (Figure 1). The types of
T. gondii involved in our analysis were grouped in “clonal lineages” (Types I, II,
and III), “recombinant” (Types I/II, I/III, and II/III), and “the other types” (TONT,
GPHT, MAS, GANGI, Africa 1, Africa 2, Caribbean 1, Br I, Br II, Br III,
ToxoDB#19, #108, #163, #206, #226, #227, #228, and #229). Supplementary
Table III shows the characteristics of these included studies and their qualities.
Figure 2 shows that 1 (7%) [37] of the 15 included studies had a low risk of bias for
selection, 13 studies (87%) [23–30, 32, 34–37] had medium risk, and 1 study (7%)
[22] had a high risk of bias. The risk of bias for comparability was low in 10
studies (67%) [22, 24, 26, 27, 29, 30, 32, 34, 35, 37] and medium in 5 studies
(33%) [23, 25, 28, 31, 36]. For exposure, 8 studies (53%) [22, 23, 25, 26, 30, 32,
34, 36] had a low risk of bias and 7 studies (47%) [24, 27–29, 31, 35, 37] had a
high risk of bias.
Analysis of contingency table
Fisher’s exact test. Discrepancy among the strain types’ proportions of the three
severities of human infection (asymptomatic infection, mild symptoms, and
toxoplasmosis) was examined with Fisher’s exact test (Monte Carlo method)
since more than 20% of the cells in the contingency table had expected counts
that were less than 5. The types’ distributions of the three human severities are
shown in Figure 3 and Supplementary Table IV. The result of Fisher’s exact test
revealed a signiﬁcant difference in types’ proportions among the three severities
(value= 254.375, p < 0.0001, see Supplementary Table V).
Multiple comparisons. As the signiﬁcant discrepancy was determined, multiple
comparisons of the proportions among the three severities for a given type were
subsequently performed using the Z-test. According to the result of multiple
comparisons (Table I), the proportions of patients with mild symptoms (13.9%)
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and toxoplasmosis (17.7%) were signiﬁcantly higher than those with no symptom
(2.7%) for Type I strains infection. For Type II strains infection, a signiﬁcant low
proportion was found in patients with mild symptoms (26.6%) compared with
those with no symptoms (51.7%) and toxoplasmosis (59.7%). Interestingly, as
with Type I strains infection, the Type III strains infection proportions of patients
with mild symptoms (8.9%) and toxoplasmosis (8.6%) were signiﬁcantly higher
than those with no symptoms (1.1%). For recombinant Types I/II and II/III, a
signiﬁcant higher proportion was found in patients with mild symptoms (3.8% and
24.1%, respectively), whereas for recombinant Type I/III, the proportion of
infected population without any symptoms (43.0%) was signiﬁcantly higher than
Figure 1. Flowchart of study selection
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the other two severities. For the other types, no signiﬁcant difference was found
among the three severities.
Meta-analysis
T. gondii types and asymptomatic infection. In total, ﬁve case–control studies [23,
24, 27, 28, 36] were included to perform the meta-analyses based
on the association between T. gondii types and asymptomatic infection.
However, our results did not reveal a signiﬁcant association between T. gondii
types and asymptomatic infection in humans (p > 0.05) (Supplementary
Table IX).
T. gondii types and infection with mild symptoms. For T. gondii types and
infection with mild symptoms, the overall OR with its 95% CI was extracted from
Figure 2. Quality assessment using the NOS for risk of bias of included studies. The absolute
number of studies was shown in boxes. For selection, 1 (7%) of the 15 included studies had low risk
of bias, 13 (87%) had medium risk, and 1 (7%) had high risk of bias; for comparability, 10 (67%)
studies had low risk and 5 (33%) studies had medium risk; and for health outcomes, 8 (53%) studies
had low risk and 7 (47%) studies had medium risk of bias
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two included case–control studies [25, 29]. No signiﬁcant difference was reported
between the case groups and control groups for Type II strains exposure (OR:
0.98, 95% CI: 0.16–6.19, p= 0.98) (Supplementary Table IX).
T. gondii types and human toxoplasmosis. In the meta-analysis of T. gondii types
and risk of human toxoplasmosis, 26 case–control studies published in 15 articles
were included [22–32, 34–37] (Supplementary Tables VI–VIII). The result
showed that the odds of Type I strains infection were signiﬁcantly higher in
patients with congenital toxoplasmosis compared with those without congenital
Figure 3. Distribution of T. gondii types by severity of human infection. Different patterns of types’
distribution of the three severities demonstrated that different types of T. gondii could cause illness in
humans at different severities. The highest proportions of Type II strains presented in the groups of
asymptomatic infection and toxoplasmosis indicated a strong association between Type II strains and
human infection
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toxoplasmosis (OR: 1.91, 95% CI: 1.31–2.80, p = 0.0009) (Table II and
Supplementary Table VI). In addition, the result showed a signiﬁcantly heightened
odds of Type III strains infection in patients with pulmonary toxoplasmosis versus
those without pulmonary toxoplasmosis (OR: 5.15, 95% CI: 1.05–25.26, p= 0.04)
(Table II and Supplementary Table VII).
Subgroup analysis. Subgroup analysis of the relationship between the
T. gondii types and congenital toxoplasmosis was performed based on the
following pathological changes: maternal seroconversion from negative to
positive; abortion, fetal death, or newborn death; cerebral toxoplasmosis in
newborns or in later life; and ocular toxoplasmosis in newborns. All subgroup
differences were small (tests for subgroup differences: p > 0.1) (Supplemen-
tary Table X). Signiﬁcant positive result was obtained in the associations of
Type I strains infection with cerebral toxoplasmosis in offspring (fetus, new-
borns, or children) (OR: 1.81, 95% CI: 1.11–2.97, p = 0.02) (Table II and
Supplementary Table VIII).
Sensitivity analysis. To identify whether the result of the meta-analysis was
signiﬁcantly affected by exclusion of the study with the highest quality or






Types I Count 7a 0a,b 95b 102
% within severities 2.7 0.0 17.4 12.5
II Count 136a 2a,b 334b 472
% within severities 52.1 25.0 61.2 57.9
III Count 3a 5b 48c 56
% within severities 1.1 62.5 8.8 6.9
I/II Count 0a 1b 3a 4
% within severities 0.0 12.5 0.5 0.5
I/III Count 111a 0b 21b 132
% within severities 42.5 0.0 3.8 16.2
II/III Count 0a 0a,b 19b 19
% within severities 0.0 0.0 3.5 2.3
The other
types
Count 4a 0a 26a 30
% within severities 1.5 0.0 4.8 3.7
Total Count 261 8 546 815
% within severities 100.0 100.0 100.0 100.0
Note: Each subscript letter denotes a subset of severities categories whose column proportions do not differ
signiﬁcantly from each other at the 0.05 level.
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the study with the greatest weight in results, sensitivity analyses were
conducted. No signiﬁcant impact was observed in the overall ORs and
95% CIs.
Publication bias. Publication bias of the studies included in this meta-analysis
was examined using funnel plots (Figure 4). All the plots in the four outcomes
approximately resembled a symmetrical funnel, hence no publication bias was
found.
Figure 4. Funnel plots of studies on human infection with T. gondii. (a) Funnel plot of studies on
asymptomatic infection; (b) Funnel plot of studies on infection with mild symptoms; (c–g) Funnel
plots of studies on toxoplasmosis. The plots approximately resembled a symmetrical funnel,
indicating the absence of publication bias
Table II. Results of meta-analysis on relationship between T. gondii type and toxoplasmosis
Toxoplasmosis
Clinical presentations Total Number Percent OR (95% CI) p value
Congenital toxoplasmosis
T. gondii type I
Case 327 64 19.6 1.91 (1.31, 2.80) 0.0009
Control 1,076 105 9.8
Pulmonary toxoplasmosis
T. gondii type III
Case 10 3 30.0 5.15 (1.05, 25.26) 0.04
Control 90 8 8.9
Cerebral toxoplasmosis in offsprings
T. gondii type I
Case 221 28 12.7 1.81 (1.11, 2.97) 0.02
Control 638 53 8.3
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Discussion
It has long been known that the Type I strains of T. gondii are highly
virulent, whereas Type II or Type III strains are less virulent or non-virulent in
mice [10, 11]. Because of the broad range of hosts that the parasite can infect, it is
unclear whether the virulence difference observed in mice will also be observed in
other hosts, such as humans. In this study, we compared the strain proportions
among the three severities of human infection, and tested if the proportions of one
given T. gondii type were signiﬁcantly different among the three severities, which
would provide an indication of the characteristics of T. gondii virulence in
humans. According to the result of Fisher’s exact test, the difference among the
three proportions was signiﬁcant (value= 254.375, p < 0.0001), suggesting
different types of T. gondii could cause illness in humans at different severity
levels, indicating different types of T. gondii might present different virulence in
humans. Various polymorphic effectors secreted from rhoptry and dense granule
contributed to the different virulence expression in different types of T. gondii
[38–40], including ROP18, ROP16, and GRA15 [41–43]. These ﬁndings were not
only observed in the mouse model, but also in HFFs, which gave a hint that the
polymorphism of these effectors might be responsible for different virulence
presented in humans, even though little was known regarding T. gondii virulence
effectors in human infection.
We also found that there was an extremely strong association between
Type II strains and human infection because the highest proportions of Type II
strains were presented in groups of asymptomatic infection and toxoplasmosis
(Figure 3). Several studies have also indicated this similar association. In North
America, Type II strains were most commonly associated with human infection,
including in patients with congenital toxoplasmosis and patients with AIDS
[5, 22]. In Europe, the same trend that Type II strains predominate in human
infection was observed [24, 44]. Such common exposure to this strain type
required our attention and this striking association was important for prevention,
diagnosis, and treatment of human infection.
Our analysis of the multiple comparison of Type I strains infection revealed
signiﬁcant higher proportions of patients with toxoplasmosis and mild symptoms
than those with asymptomatic infection, which suggested that Type I strains
mainly caused apparent diseases or mild symptoms, potentially with a medium to
high level of virulence in humans. Previously, a cross-sectional study reported a
predominance of Type I parasites infection in ocular toxoplasmosis patients [45],
whereas in another study, Type I strains were reported to be more frequently
associated with congenital toxoplasmosis in humans [46]. According to our
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meta-analysis, a signiﬁcant association was observed between Type I T. gondii
infection and congenital toxoplasmosis (OR: 1.91, p = 0.0009). It is reported that
the Type I strains could generate signiﬁcantly higher levels of parasitemia, and
increase both the risk of transplacental transmission and the severity of infection in
fetus or newborn [5, 47]. Our subgroup analysis conﬁrmed the signiﬁcant
association of Type I strains infection with cerebral toxoplasmosis in offspring
(fetus, newborns, or children) (OR: 1.81, p = 0.02). The mechanism for this was
unknown, but it was possible that during pregnancy, the acute infection acquired
from the Type I parasites could cause higher parasitemia and an increased rate of
congenital infection [5, 31], since the parasite was apt to infect the nervous system,
therefore, the Type I strains were predominant in congenital toxoplasmosis [31]. In
addition, the mother’s anti-toxoplasma antibodies might inﬂuence the prenatal or
postnatal ontogeny of a child [48].
To our surprise, the Type III strains infection proportions of patients with
mild symptoms and toxoplasmosis were signiﬁcantly higher than those with
asymptomatic infection, similar to the Type I strains infection. One difference,
however, was that the proportion of patients with mild symptoms was a little
higher than those with toxoplasmosis for Type III infection, while the reverse
result was observed for Type I infection. These results indicated that Type III
strains of T. gondii might present medium virulence in humans, unlike their
avirulence in laboratory mice. In our meta-analysis, the signiﬁcant association
between the Type III strains infection and pulmonary toxoplasmosis was
conﬁrmed (OR: 5.15, 95% CI: 1.05–25.26, p = 0.04). The pathomechanism of
Type III parasites in pulmonary toxoplasmosis was unknown, but it was reported
that Type III parasites infection could result in change of a critical enzyme TDO2,
in the kynurenine pathway in infected cells [33], this ﬁnding implicated a complex
pathogenesis of Type III T. gondii.
In this study, we revealed an apparent difference of T. gondii virulence
between laboratory mice and humans, at least for the three clonal lineages and their
recombinant strains. It was possible that there was difference in susceptibility to
T. gondii, or to different types of the parasite, between mice and humans.
Alternatively, it was also possible that there was difference in pathogenic
mechanism of the parasite during infection between mice and humans. However,
it was notable that in addition to the parasite types, other factors, such as the
genetic backgrounds of hosts, immunity condition of hosts, and the timing of
primary infection might also play a role in outcomes of human infection. In
addition, since human isolates were mainly collected from symptomatic cases, the
information of T. gondii types from asymptomatic cases was always neglected and
limited. Including a larger number of studies and studies with larger sample sizes
would be necessary to conﬁrm and extend the ﬁndings in this study.
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Conclusions
In conclusion, the meta-analysis suggested different clonal lineages of
T. gondii might exhibit different virulence and caused different outcomes in
humans. Type I strains infection was signiﬁcantly associated with an increased risk
of human congenital toxoplasmosis, especially the cerebral toxoplasmosis in
offspring. Type III parasites showed a signiﬁcant association with human pulmo-
nary toxoplasmosis.
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